Literature DB >> 4555278

A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease.

J E Walker, J W Albers, W W Tourtellotte, W G Henderson, A R Potvin, A Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4555278     DOI： 10.1016/0021-9681(72)90171-3

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN： 0021-9681


× No keyword cloud information.
  7 in total

1.  A battery of tests for evaluating steadiness in clinical trials.

Authors:  A R Potvin; J W Albers; R F Stribley; W W Tourtellotte; R W Pew
Journal:  Med Biol Eng       Date:  1975-11

2.  Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.

Authors:  S G Bowes; P K Clark; A Charlett; C J O'Neill; A L Leeman; C Weller; P W Nicholson; A A Deshmukh; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 3.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 4.  Early Parkinson's disease: what is the best approach to treatment.

Authors:  A H Hristova; W C Koller
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 5.  NMDA receptors in clinical neurology: excitatory times ahead.

Authors:  Lorraine V Kalia; Suneil K Kalia; Michael W Salter
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

Review 6.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 7.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.